Chipscreen(SH:688321) Ge Long Hui A P P·2026-01-08 08:04Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of its new anti-tumor drug, Xioroni, which is expected to show significant efficacy in treating pancreatic cancer [1][2]. Group 1: Drug Development - The company has developed Xioroni, a novel small molecule anti-tumor drug with a unique chemical structure, which has global intellectual property protection [1]. - Xioroni exhibits a multi-pathway anti-tumor mechanism by inhibiting multiple kinase targets such as AuroraB, CSF1R, and VEGFR/PDGFR/c-Kit, demonstrating comprehensive anti-pancreatic cancer effects [1]. Group 2: Clinical Trial Results - Phase II clinical trial data indicates that Xioroni combined with standard AG chemotherapy (albumin-bound paclitaxel and gemcitabine) shows better objective response rates, disease control rates, and progression-free survival compared to historical data of AG chemotherapy [2]. - The safety and tolerability of Xioroni in patients have been reported as good, suggesting a favorable profile for further development [2]. Group 3: Future Expectations - The company anticipates that combining Xioroni with PD-1 monoclonal antibodies and chemotherapy will further improve clinical efficacy and extend survival time for patients with advanced pancreatic cancer [2].